Abstract
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the commonest skin malignancies and if diagnosed early have a good prognosis. Conversely, metastatic disease is rarely associated with a very poor prognosis. Locally advanced BCC is also uncommon and may not be amendable to surgery, radiation therapy or photodynamic therapy. The activation of the hedgehog pathway occurs in 90% of BCCs and inhibition of this pathway with well tolerated oral agents has resulted in an important therapeutic option in some patients with locally advanced or metastatic BCC. In contrast, metastatic SCC tends to behave biologically more aggressively and cisplatin based chemotherapy has very limited efficacy.
Keywords: Chemotherapy, targeted therapy, basal cell carcinoma, squamous cell carcinoma, nonmelanoma.
Current Cancer Therapy Reviews
Title:Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Volume: 12 Issue: 3
Author(s): Vamsee Torri
Affiliation:
Keywords: Chemotherapy, targeted therapy, basal cell carcinoma, squamous cell carcinoma, nonmelanoma.
Abstract: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the commonest skin malignancies and if diagnosed early have a good prognosis. Conversely, metastatic disease is rarely associated with a very poor prognosis. Locally advanced BCC is also uncommon and may not be amendable to surgery, radiation therapy or photodynamic therapy. The activation of the hedgehog pathway occurs in 90% of BCCs and inhibition of this pathway with well tolerated oral agents has resulted in an important therapeutic option in some patients with locally advanced or metastatic BCC. In contrast, metastatic SCC tends to behave biologically more aggressively and cisplatin based chemotherapy has very limited efficacy.
Export Options
About this article
Cite this article as:
Torri Vamsee, Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573394713666161229124633
DOI https://dx.doi.org/10.2174/1573394713666161229124633 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Glucocorticoid Receptor Functions in HeLa Cells Are Perturbed by 2,3,8,9-tetrachlorodibenzo-p-dioxin (TCDD)
Drug Metabolism Letters Calixarenes in Bio-Medical Researches
Current Medicinal Chemistry Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Subject Index to Volume 4
Current Molecular Medicine CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Anti-Cancer Agents in Medicinal Chemistry Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery MicroRNAs in Skin Response to UV Radiation
Current Drug Targets Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Tumor-Induced Metabolism and T Cells Located in Tumor Environment
Current Cancer Drug Targets Involvement of Cytoskeleton in AhR-Dependent CYP1A1 Expression
Current Drug Metabolism Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design Activation of Integrin β1 Mediates the Increased Malignant Potential of Ovarian Cancer Cells Exerted by Inflammatory Cytokines
Anti-Cancer Agents in Medicinal Chemistry